House committee investigates Wyeth's marketing of Rapamune

06/13/2010 | Wall Street Journal, The

The House Oversight and Government Reform Committee is investigating whether Wyeth illegally promoted its drug Rapamune for unapproved use, including for the prevention of organ rejection after heart, liver, pancreas and islet cell transplants. FDA approval for the product is limited to preventing organ rejection after a kidney transplant.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park